Navigation Links
CEL-SCI Launches Study to Determine Long Lasting Beneficial Effects of its Rheumatoid Arthritis Vaccine

Results expected to Support Licensing Activities

VIENNA, Va., Jan. 7 /PRNewswire-FirstCall/ -- CEL-SCI Corporation (NYSE Alternext US: CVM) announced today the initiation of a definitive study of its new rheumatoid arthritis treatment vaccine (CEL-2000) to determine the long-lasting beneficial effects on animals with the disease. The study is being conducted at the request of a large pharmaceutical company which is evaluating the possibility of acquiring a global license for the vaccine from CEL-SCI. The long-term results, previously presented at the 6th annual GTCbio Vaccine conference, for the CEL-2000 vaccine were better than or comparable to those for Enbrel(R), a leading treatment for people with rheumatoid arthritis.

"We are very excited to see a prominent pharmaceutical company express interest in licensing the vaccine," said Geert Kersten, CEL-SCI's Chief Executive Officer. "As a result of the very good data with this novel approach, we believe that the prospects for licensing the vaccine are promising."

The definitive experiment will confirm the efficacy and durability of the response to the vaccine and will further assess the safety of the CEL-2000 vaccine, in preparation for possible human trials. CEL-2000 may also offer a number of other potential advantages over existing rheumatoid arthritis treatments, such as Enbrel. The data from animal studies of rheumatoid arthritis using CEL-2000 treatment vaccine demonstrated that CEL-2000 is an effective treatment against arthritis with fewer administrations than those required by other anti-rheumatoid arthritis treatments, including Enbrel(R). CEL-2000 is also potentially a more disease type specific therapy is calculated to be significantly less expensive and may be useful in patients unable to tolerate or who may not be responsive to existing anti-arthritis therapies.

Rheumatoid arthritis treatments comprise a $13 billion market. Enbrel, a leading rheumatoid arthritis treatment sold by Amgen and Wyeth, reported US sales in 2007 of about $3.2 billion. Enbrel is a soluble recombinant protein of a human TNF-alpha receptor linked to human IgG Fc. In some cases, human or humanized monoclonal antibodies specific against TNF-alpha have also been used for therapy in rheumatoid arthritis. These therapies remove or inactivate TNF-alpha, a natural human cytokine required in many immune functions for normal defenses.

CEL-SCI's rheumatoid arthritis vaccine CEL-2000 was discovered as part of work with the Company's ongoing research and development activities with its L.E.A.P.S.(TM) (Ligand Epitope Antigen Presentation System) technology. L.E.A.P.S. is a novel T-cell modulation platform technology that enables CEL-SCI to design and synthesize proprietary immunogens. Any disease for which an antigenic sequence has been identified, such as infectious, parasitic, malignant or autoimmune diseases and allergies, are potential therapeutic or preventive sites for the application of L.E.A.P.S. technology.

The concept behind the L.E.A.P.S. technology is to directly mimic cell/cell interactions on the T-cell surface with synthetic peptides. The L.E.A.P.S. constructs containing the antigenic disease epitope linked to a T-cell binding ligand (TCBL) can be manufactured by peptide synthesis or by covalently linking the two peptides. Depending upon the type of L.E.A.P.S. construct and TCBL used, CEL-SCI is able to direct the outcome of the immune response towards the development of T-cell function with primarily effector T-cell functions (T Lymphocyte; helper/effector T lymphocyte, type 1 or 2 [Th1 or Th2], cytotoxic [Tc] or suppressor [Ts]). Therefore, it would appear that the L.E.A.P.S. construct represents a chimeric peptide with bi-functional behavior.

CEL-SCI Corporation is developing products that empower immune defenses. Its lead product is Multikine(R) which is being readied for a global Phase III trial. The Company has operations in Vienna, Virginia, and Baltimore, Maryland. CEL-SCI's other products, which are currently in pre-clinical stage, have shown protection against a number of diseases in animal tests and are being tested against diseases associated with bio-defense and avian flu.

When used in this report, the words "intends," "believes," "anticipated" and "expects" and similar expressions are intended to identify forward-looking statements. Such statements are subject to risks and uncertainties which could cause actual results to differ materially from those projected. Factors that could cause or contribute to such differences include, an inability to duplicate the clinical results demonstrated in clinical studies, timely development of any potential products that can be shown to be safe and effective, receiving necessary regulatory approvals, difficulties in manufacturing any of the Company's potential products, inability to raise the necessary capital and the risk factors set forth from time to time in CEL-SCI Corporation's SEC filings, including but not limited to its report on Form 10- K for the year ended September 30, 2007. The Company undertakes no obligation to publicly release the result of any revision to these forward-looking statements which may be made to reflect the events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

SOURCE CEL-SCI Corporation
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. CEL-SCI Presents Favorable Data for Leaps Vaccine Technology at Prestigious Immunology Conference
2. CEL-SCI Corporation Reports Second Quarter 2008 Financial Results
3. CEL-SCI CORPORATION Announces Results of 2008 Annual Meeting of Shareholders and Provides Update on Ground-breaking Activities Regarding Construction of Manufacturing Facility for Pivotal Phase III Cancer Trial
4. CEL-SCI Corporation Releases Letter to Shareholders
5. CEL-SCI Corporation Announces Adoption of Shareholder Rights Plan
6. Comprehensive Review of Cancer Immnunotherapies Published By CEL-SCI
7. Surf Sweets Launches Natural, Organic Candy Line at More Than 250 Toys"R"Us Stores Across the Country
8. Launches The Child Resource Center
9. First Service Design Firm Launches in United States
10. The Doctors Company Launches Southeast Legal Summit to Provide Industry's Best Claims Defense for Physicians
11. Florida Breast Augmentation Surgeon Launches State-of-the-Art Website Reflecting his Unique Approach
Post Your Comments:
(Date:11/24/2015)... ... 24, 2015 , ... Preparing for the LDT Regulation:, CLIA Won’t Satisfy the ... , FDA has long asserted that design and manufacture of Laboratory Developed Tests ... do not meet the device regulations. , Come up short in an inspection and ...
(Date:11/24/2015)... ... November 24, 2015 , ... Brillouin Energy Corp. Congress and ... developer of renewable energy technologies capable of producing commercially useful amounts of thermal ... its WET™ and HHT™ Boiler System reactor core modules were presented to Congress ...
(Date:11/24/2015)... , ... November 24, 2015 , ... ... to share their knowledge and experiences at a live taping of the next ... Center for the Cure of Gastrointestinal Cancers 2015 Symposium at Georgetown University Hotel ...
(Date:11/24/2015)... ... 2015 , ... Serenity Point Rehabilitation, a holistic treatment center for substance abuse ... of the staff members at their recovery center. The videos highlight some of the ... of the things that make their recovery program so unique. , “Making the decision ...
(Date:11/24/2015)... ... ... Shoulder , LLC launched their Pro Vest, the latest version of their widely popular weight ... under 10 hours. , The campaign, which will continue to run through ... market. , The PRO Vest provides consumers with a less expensive, one-size fits all comfort ...
Breaking Medicine News(10 mins):
(Date:11/24/2015)... , Nov. 24, 2015  Thanks to a donor ... St. Mary,s Medical Center,s Sister Diane Grassilli Center for ... capabilities in San Francisco . ... friend, stepped forward with a gift of $617,320 that ... Digital Mammography with Tomosynthesis and Whole Breast Ultrasound. Tomosynthesis, ...
(Date:11/24/2015)... 2015 /PRNewswire/ - ESSA Pharma Inc. ("ESSA" or the ... that the first patient has been enrolled in ESSA,s ... for metastatic castration-resistant prostate cancer ("mCRPC"). ... --> the United States and ... clinical trial, ESSA intends to demonstrate the safety, tolerability, ...
(Date:11/24/2015)... --> --> ... by Product Type (Bone Graft, Bine Graft Substitute, Platelet Rich ... Lumbar Interbody Fusion), End User, and Geography - Global Forecast ... at $1.90 Billion in 2014 and is expected to reach ... the forecast period of 2015 to 2020. Browse ...
Breaking Medicine Technology: